Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN: Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.
moreShow FUSN Financials
Recent trades of FUSN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by FUSN's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Actinium-225 and checkpoint inhibitor combination therapy Sep. 20, 2022
-
Patent Title: Endosialin-binding antibody May. 03, 2022
-
Patent Title: Igf-1r monoclonal antibodies and uses thereof Oct. 09, 2018
Federal grants, loans, and purchases
Followers on FUSN's company Twitter account
Number of mentions of FUSN in WallStreetBets Daily Discussion
Recent insights relating to FUSN
Recent picks made for FUSN stock on CNBC
ETFs with the largest estimated holdings in FUSN
Flights by private jets registered to FUSN